Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials

PR Newswire December 13, 2016

aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference

PR Newswire December 9, 2016

aTyr Pharma Enters into $20 Million Credit Facility

PR Newswire November 21, 2016

aTyr Pharma Announces Third Quarter 2016 Operating Results

PR Newswire November 14, 2016

aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

PR Newswire October 24, 2016

aTyr Pharma Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society

PR Newswire October 6, 2016

aTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society

PR Newswire September 29, 2016

aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research

PR Newswire September 21, 2016

Final Results

UK Regulatory news services, from the LSE June 30, 2016

Transaction in Own Shares

UK Regulatory news services, from the LSE June 28, 2016

Holding(s) in Company

UK Regulatory news services, from the LSE June 28, 2016

Holding(s) in Company

UK Regulatory news services, from the LSE June 20, 2016

Net Asset Value(s)

UK Regulatory news services, from the LSE June 20, 2016

Main Securities Market Notice

UK Regulatory news services, from the LSE June 20, 2016

Form 8.5 (EPT/NON-RI) Ball Corp

UK Regulatory news services, from the LSE June 20, 2016

Issue of ETFS Metal Securities Limited

UK Regulatory news services, from the LSE June 20, 2016

Second Price Monitoring Extn

UK Regulatory news services, from the LSE June 16, 2016

Price Monitoring Extension

UK Regulatory news services, from the LSE June 16, 2016

aTyr Pharma to Present at Jefferies 2016 Healthcare Conference

PR Newswire June 3, 2016

aTyr Pharma Announces First Quarter 2016 Operating Results

PR Newswire May 11, 2016